Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

Also called NCT02517320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 293 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02517320
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02517320. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2016-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
MT-3995 Low
Intervention (Drug)
MT-3995 Middle
Intervention (Drug)
MT-3995 High
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02517320
Content hash
a5908f638195c6d2eb2b094c596532f23ee8fbc50620f93766630d585f7407a3